Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-607-0800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$206.63 million
Profitability
Miscellaneous
Employees113
Next Earnings Date11/21/2019 (Confirmed)
OptionableOptionable
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its earnings results on Tuesday, August, 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.98 by $0.01. The biotechnology company had revenue of $57.26 million for the quarter, compared to analysts' expectations of $56.59 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
How can I listen to Enanta Pharmaceuticals' earnings call?
Enanta Pharmaceuticals will be holding an earnings conference call on Thursday, November 21st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ENTA?
4 brokerages have issued twelve-month target prices for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $101.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.
What is the consensus analysts' recommendation for Enanta Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.
Has Enanta Pharmaceuticals been receiving favorable news coverage?
News articles about ENTA stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Ascendis Pharma A/S (ASND), The Medicines (MDCO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), Allakos (ALLK), Evotec (EVTCY), Alkermes (ALKS), BridgeBio Pharma (BBIO), FibroGen (FGEN), HUTCHISON CHINA/S (HCM) and Taro Pharmaceutical Industries (TARO).
What other stocks do shareholders of Enanta Pharmaceuticals own?
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
- Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
- Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
- Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)
Who are Enanta Pharmaceuticals' major shareholders?
Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.49%), Rhumbline Advisers (0.26%), Alps Advisors Inc. (0.20%), New York State Teachers Retirement System (0.20%), California Public Employees Retirement System (0.18%) and Mackay Shields LLC (0.11%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Which major investors are selling Enanta Pharmaceuticals stock?
ENTA stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Dupont Capital Management Corp, Alps Advisors Inc., Navellier & Associates Inc, Systematic Financial Management LP, New York State Teachers Retirement System and Advantage Investment Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.
Which major investors are buying Enanta Pharmaceuticals stock?
ENTA stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, California Public Employees Retirement System, Russell Investments Group Ltd., State of Alaska Department of Revenue, Wedge Capital Management L L P NC, Mackay Shields LLC, Pacer Advisors Inc. and Rhumbline Advisers. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $62.03.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $1.22 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.
What is Enanta Pharmaceuticals' official website?
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
